Trial Profile
National survey about the aggravation by respiratory syncytial virus infection in children with immunodeficiency
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 Jan 2018
Price :
$35
*
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- 02 Apr 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 26 May 2016 New trial record